Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Endometrial Cancer

Endometrial Cancer

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Endometrial Cancer

118 trials tracked for Endometrial Cancer: 9 in phase 3 or 4 and 5 with published results. The most-cited published study has 372 citations.

118Trials tracked
9Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 9 Phase 2 82 Phase 1 7 Other / NA 20
  1. Phase 3 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Completed · 372 cited
  2. Phase 3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed · 235 cited
  3. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 153 cited
  4. Phase 3 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Completed · 67 cited
  5. Phase 3 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed · 10 cited
  6. Phase 3 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study Completed
Show 44 more trials
  1. Phase 3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
  2. Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed
  3. Phase 3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed
  4. Phase 2 A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Completed
  5. Phase 2 SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma Completed
  6. Phase 2 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Completed
  7. Phase 2 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  8. Phase 2 A Trial for Patients With Advanced/Recurrent Endometrial Cancer Completed
  9. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  10. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  11. Phase 2 Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  12. Phase 2 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Completed
  13. Phase 2 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Completed
  14. Phase 2 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Completed
  15. Phase 2 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed
  16. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  17. Phase 2 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Completed
  18. Phase 2 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Completed
  19. Phase 2 A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Completed
  20. Phase 2 A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer Completed
  21. Phase 2 Survivorship Promotion In Reducing IGF-1 Trial Completed
  22. Phase 2 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Completed
  23. Phase 2 ZW25 in Women With Endometrial Cancers Completed
  24. Phase 2 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed
  25. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  26. Phase 2 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed
  27. Phase 2 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed
  28. Phase 2 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  29. Phase 2 Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression Completed
  30. Phase 2 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  31. Phase 2 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed
  32. Phase 2 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Completed
  33. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  34. Phase 2 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed
  35. Phase 2 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Completed
  36. Phase 2 A Study of Nivolumab in Selected Uterine Cancer Patients Completed
  37. Phase 2 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Completed
  38. Phase 2 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer Completed
  39. Phase 2 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed
  40. Phase 2 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed
  41. Phase 2 Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  42. Phase 2 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  43. Phase 2 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed
  44. Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed

Showing the 50 most-cited and recently-updated of 118 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Endometrial Cancer: what the trials found

Pembrolizumab demonstrated significant improvements in progression-free survival (PFS) for both mismatch repair proficient (pMMR) and all-comer participants compared to standard treatments 4. In a smaller cohort, Pembrolizumab also showed a statistically significant improvement in overall response rate (ORR) 12.

Several agents were evaluated without demonstrating statistically significant differences in primary endpoints. Bevacizumab did not show significant differences in median progression-free survival 3 or in progression-free survival and overall survival across multiple trials 9. Lenvatinib showed no significant difference in progression-free survival for pMMR participants 5 or all randomized participants 5, nor was there a statistically significant difference in its ORR or overall survival in pMMR patients 7. Additionally, AEZS-108/zoptarelin doxorubicin did not show significant differences compared to doxorubicin regarding overall survival, objective response rate, or progression-free survival 6.

Radiation therapy was associated with a statistically significant decrease in the EPIC Bowel Domain Score at 5 weeks 2, though the percentage of patients with acute Grade 2+ gastrointestinal toxicity did not differ significantly 2. Radiation also showed significant differences in changes to the EPIC Urinary Domain score 2. Carboplatin was evaluated across multiple trials without reported outcome metrics for comparison [15, 16, 19].

Recent results — preliminary, needs further review

  • * The implementation of an AH-HA Tool in the EPIC EHR significantly increased the proportion of patients reporting discussion of at least one non-ideal or missing cardiovascular health (CVH) topic compared to standard practice 1. * Onapristone ER was evaluated in a Phase 2 trial 11.

For the clinician treating this condition

  • Pembrolizumab is associated with statistically significant improvements in progression-free survival for both pMMR and all-comer populations 4.
  • Bevacizumab, Lenvatinib, and AEZS-108/zoptarelin doxorubicin did not show statistically significant improvements over their respective comparators in primary efficacy endpoints (PFS, OS, or ORR) [3, 5, 6, 7, 9].
  • Radiation therapy is associated with a statistically significant reduction in the EPIC Bowel Domain Score at 5 weeks post-treatment 2.

AI synthesis of 10 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
Oncology Meta-analysis
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer Mapping the Research Landscape of Immune Therapy for Endometrial Cancer
This systematic review uses a bibliometric analysis to map the landscape of immune checkpoint inhibitor research in endometrial cancer. The …
A large-scale analysis maps out how researchers worldwide are studying immune checkpoint inhibitors to treat endometrial cancer.
Frontiers Jun 8, 2026
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer
Allergy & Immunology Meta-analysis
PD-1/PD-L1 inhibitors plus chemotherapy improve survival in advanced endometrial cancer Immunotherapy combo extends life in advanced endometrial cancer
A meta-analysis of 4,052 patients from RCTs found that adding PD-1/PD-L1 inhibitors to chemotherapy improved overall survival (median 43.7 v…
Adding immunotherapy to chemo boosted survival by over 14 months in advanced endometrial cancer, a new analysis finds.
Frontiers Jun 2, 2026
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility
Oncology Sys. Review
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility New Plan Cuts Cancer Risk for High-Risk Women
This narrative review addresses ovarian, endometrial, and fallopian tube cancer in women with inherited gynecologic cancer susceptibility.
Women with strong family histories of ovarian or uterine cancer can now take smarter, personalized steps to reduce their risk — and it’s cha…
Frontiers Apr 28, 2026
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications
OB/GYN & Women's Health Sys. Review
Narrative review links microbiome dysbiosis to gynecological cancer pathogenesis and potential therapeutic applications Microbiome changes may help explain how gynecological cancers start and grow
This narrative review examines the role of the human microbiome in gynecological malignancies, including cervical, ovarian, endometrial, vul…
New review suggests microbiome shifts could be key to understanding gynecological cancers, opening doors for better prevention and treatment…
Frontiers Apr 23, 2026
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer
Oncology Meta-analysis
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer Tumor Budding Linked to Worse Outcomes in Cervical and Endometrial Cancer
This Bayesian meta-analysis of 18 observational cohort studies involving 3320 patients with cervical or endometrial cancer evaluated the pro…
Small clusters of cells breaking away from cervical and endometrial tumors signal more aggressive disease and worse survival outcomes.
Apr 9, 2026
Molecular-profile guided adjuvant treatment shows cost-effectiveness versus standard VBT in HIR-EC
OB/GYN & Women's Health RCT
Molecular-profile guided adjuvant treatment shows cost-effectiveness versus standard VBT in HIR-EC Can a new cancer test save money without sacrificing quality of life?
A phase 3 RCT of 564 women with early-stage high-intermediate risk endometrial cancer found molecular-integrated-profile guided adjuvant tre…
A new cancer test guided by molecular profiles cut healthcare costs for endometrial cancer patients without lowering their quality of life o…
Apr 5, 2026

Questions about Endometrial Cancer

Is there a link between the microbiome and Endometrial Cancer?

Yes, research links microbiome changes (dysbiosis) to endometrial cancer risk through inflammation, immune effects, and estrogen metabolism.

Full answer →
What are the current research trends for immune checkpoint inhibitors in Endometrial Cancer?

Current research focuses on PD-1/PD-L1 inhibitors, especially for MSI-H tumors, combination therapies, and understanding molecular subtypes to improve immunotherapy response in endometrial cancer.

Full answer →
Does combined pelvic and para-aortic lymphadenectomy improve survival for Endometrial Cancer?

Combined pelvic and para-aortic lymphadenectomy may improve survival in intermediate/high-risk endometrial cancer, but evidence is mixed and not definitive for all stages.

Full answer →